プレプリント / バージョン1

Infectivity of omicron BQ.1.1 comparison with other strains of SARS-Cov-2 in Japan

##article.authors##

  • Kurita, Junko Department of Nursing, Faculty of Sport and Health Science, Daito Bunka University
  • Tamie Sugawara Infectious Disease Surveillance Center, National Institute of Infectious Diseases
  • Yasushi Ohkusa Infectious Disease Surveillance Center, National Institute of Infectious Diseases

DOI:

https://doi.org/10.51094/jxiv.294

キーワード:

SARS-CoV-2、 effective reproduction number、 BQ.1.1.、 omicron variant strain、 vaccine coverage、 waning in vaccine effectiveness

抄録

Abstract

Background: After decline of BA.5 sublineage of omicron variant strain of SARS-CoV-2, BQ.1.1. sublineage had been emerging.

Object: The object of this study was to estimate infectivity of BQ.1.1. sublineage controlling other factors that might affect BQ.1.1’s infectivity including vaccine effectiveness and waning, the mutated strain other than BQ.1.1, and countermeasuresBQ.1.1.

Method: The effective reproduction number(R(t)) was regressed on shares of BQ.1.1. as well as vaccine coverage, vaccine coverage with some delay, temperature, humidity, mobility, share of the other mutated strains, counter measures including Go To Travel Campaign and an Olympic Games. The study period was February, 2020 through the end of year 2022, as of January 31, 2023.

Results : We selected the specification with 90 days lag of waning. In this specification, Goto Travel Campaign and Olympic games were significantly negative and thus these event reduced infectivity. The estimated coefficient of BQ.1.1 sublineage of omicron variant strain was positive but insignificant.

Discussion: The obtained estimated results showed that BQ.1.1 may not have higher infectivity than BA.1, BA.2, BA.5 or other minor sublineage of omicron variant strains. It might be consistent with slower and gradually replacement from BA.5 to BQ.1.1.

利益相反に関する開示

No author has any conflict of interest, financial or otherwise, to declare in relation to this study.

ダウンロード *前日までの集計結果を表示します

ダウンロード実績データは、公開の翌日以降に作成されます。

引用文献

European Centre for Disease Prevention and Control. Epidemiological update: SARS-CoV-2 Omicron sub-lineages BA.4 and BA.5. https://www.ecdc.europa.eu/en/news-events/epidemiological-update-sars-cov-2-omicron-sub-lineages-ba4-and-ba.5. [accessed on January 22, 2023]

National Institute of Infectious Diseases. Updated Situation of COVID-19 Outbreak (July 13,2022) https://www.niid.go.jp/niid/ja/2019-ncov/11309-covid19-ab90th.html (in Japanese) [accessed on January 20, 2023]

Ministry of Health, Labour and Welfare. Visualizing the data: information on COVID-19 infections. https://covid19.mhlw.go.jp/en/ [accessed on February 17, 2023]

Kurita J, Sugawara T, Ohkusa Y. Estimating Event Ban Effects on COVID-19 Outbreak in Japan. Journal of Health Science and Development 2021. 4: https://www.innovationinfo.org/articles/JHSD/JHSD-137.pdf

Tokyo metropolitan Government. Data of COVID-19 monitoring meeting in metropolitan Tokyo. https://www.bousai.metro.tokyo.lg.jp/taisaku/saigai/1013388/index.html (in Japanese) [accessed February 21,2023].

Prime Minister of Japan and His Cabinet. COVID-19 Vaccines. https://japan.kantei.go.jp/ongoingtopics/vaccine.html [accessed on February 17, 2023]

Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med 2021:NEJMoa2114583.

Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021:NEJMoa2114114.

Li B, Deng A, Li K, et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. medRxiv 2021.07.07.21260122; doi: https://doi.org/10.1101/2021.07.07.21260122

ダウンロード

公開済


投稿日時: 2023-02-21 05:23:16 UTC

公開日時: 2023-02-24 06:50:44 UTC
研究分野
一般医学・社会医学・看護学